Medical devices, healthcare technology and the business of care
PMA approval · P200035

OrganOx metra System

Organox Limited · Decision date Dec 9, 2021

MEDTECHLEDGER EXPLANATIONP200035

What did the FDA approve?

The FDA decision dated 2021-12-09 for OrganOx metra System (P200035) carries the action code APPR, with no supplement type or reason supplied in the record. The listed scope is the approved indication for a transportable device intended to sustain donor livers in a functioning state for a total preservation time of up to 12 hours, for grafts from donors after brain death (DBD) or from donors after circulatory death (DCD) aged 40 years or younger, with 20 minutes or less of functional warm ischemic time measured from donor systolic blood pressure below 50 mmHg, and macrosteatosis of 15% or less.

The record names a device category of normothermic machine perfusion for donor livers before transplantation, with product code QQK and applicant Organox Limited, under Gastroenterology and Urology. The statement describes a preservation purpose in a near-physiologic, normothermic and functioning state intended for a potential transplant recipient; it does not report trial data, safety or effectiveness findings, or any additional indication beyond the wording given.

FDA approval order statement

Approval for the OrganOx metra System. The device is approved for the following indication: The OrganOx metra is a transportable device intended to be used to sustain donor livers destined for transplantation in a functioning state for a total preservation time of up to 12 hours.The OrganOx metra device is suitable for liver grafts from donors after brain death (DBD), or liver grafts from donors after circulatory death (DCD) <=40 years old, with <=20 mins of functional warm ischemic time (time from donor systolic blood pressure <50 mmHg), and macrosteatosis <=15%, in a near-physiologic, normothermic and functioning state intended for a potential transplant recipient.
Regulatory pathway
Original PMA
Clinical specialty
Gastroenterology, Urology
Decision date
Dec 9, 2021

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P200035
Regulatory pathway
Premarket approval application
Product code
QQK
Decision code
APPR
Decision date
Dec 9, 2021
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Normothermic machine perfusion system for the preservation of donor livers prior to transplantation.

Product code
QQK
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P200035 received

    Application receipt date recorded by FDA.

  2. P200035 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P200035. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200035

Product / regulatory recordCompanyPathwayDecision dateSource
Organox LimitedPMA supplementOct 9, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Organox Limited

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Oxford Science Park, Magdalen Centre, Robert Robinson Ave., Oxford, OX4 4GA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records